On the stock market since 2016, it operates in the world of health and science. It has 41 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 39% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $11.8M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 565% — still a thick cushion, though costs have been eating into it lately.
Over the last 12 months, company executives reported 19 buys and 0 sells. Management buying with its own money is usually read as a good sign.
Over the last 3 years, sales fell about 43% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The company’s market value is 83 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, PAVM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PAVM is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.